Mesoblast (ASX:MSB) Current Accrued Expense: A$0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:MSB Mesoblast Ltd ASX:MSB
34 GF Score
Price A$2.03
! 4 Warning Signs
View Full Analysis

What is Mesoblast Current Accrued Expense?

Mesoblast ASX:MSB -0.98% 34 Current Accrued Expense is A$0.00 Mil as of Mar. 2026. GuruFocus rates ASX:MSB with a GF Score™ of 34/100. The stock has 4 warning signs investors should review.

Mesoblast's Current Accrued Expense for the quarter that ended in Mar. 2026 was A$0.00 Mil.

Mesoblast's quarterly Current Accrued Expense increased from Sep. 2025 (A$0.00 Mil) to Dec. 2025 (A$9.72 Mil) but then declined from Dec. 2025 (A$9.72 Mil) to Mar. 2026 (A$0.00 Mil).

Mesoblast Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Mesoblast's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Mesoblast Current Accrued Expense Chart

Mesoblast Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Mesoblast Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 9.72 0.00 0.00
ASX:MSB
34GF Score
Mesoblast Ltd ASX:MSB
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Mesoblast Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of A$0.00 Mil mean?
Mesoblast (ASX:MSB) has a Current Accrued Expense of A$0.00 Mil as of Mar. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Mesoblast and its competitors.
Is Mesoblast's Current Accrued Expense too high?
Mesoblast's current Current Accrued Expense is A$0.00 Mil. Overall, Mesoblast has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Mesoblast's Current Accrued Expense compare to VRTX and REGN?
Mesoblast's Current Accrued Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Mesoblast and its competitors. Mesoblast's current Current Accrued Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mesoblast stock overvalued right now?
Mesoblast (ASX:MSB) has a current Current Accrued Expense of A$0.00 Mil. The current Current Accrued Expense is A$0.00 Mil. Mesoblast's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Mesoblast (ASX:MSB), the current Current Accrued Expense is A$0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Mesoblast Business Description

Address 55 Collins Street, Level 38, Melbourne, VIC, AUS, 3000
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
34GF Score

Get the complete analysis for ASX:MSB

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.03
Price